INS and cancer: It is activated by insulin, glucocorticoids, tumor necrosis factor-alpha (TNFα), and estrogens [159] and induces cancer progression by activation of the JAK2/STAT3 [162], PI3K, and MAPK pathways [163–166] through LEPR-B.